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introduction
What Will It Take to  
Address the Global Threat of 
Antibiotic Resistance?
Steven J. Hoffman and Kevin Outterson
Of the many global health challenges facing the world today, only a small number require global collective action. Most health chal-
lenges can be fully addressed through action at local, 
regional or national levels.
What kind of actions must be taken to address the 
global threat of antibiotic resistance (ABR)? What 
legal, political and economic tools might be needed to 
achieve this level of action?
In March 2015 the Dag Hammarskjöld Foundation1 
convened a workshop in Uppsala, Sweden to address 
these questions in partnership with the Global Strat-
egy Lab,2 the Journal of Law, Medicine & Ethics 
(JLME),3 the Norwegian Institute of Public Health,4 
and ReAct – Action on Antibiotic Resistance.5 Eleven 
concise articles were commissioned to explore whether 
ABR depended on global collective action, and if so, 
what tools could help states and non-state actors to 
achieve it. This work built upon previous efforts of the 
Dag Hammarskjöld Foundation and its partners to 
address ABR, as well as instigate further research that 
is needed to inform relevant global policies, initiatives, 
and actions going forward.
The Problem of Antibiotic Resistance
This peer-reviewed JLME series begins with a detailed 
description of ABR. The medical evidence is clear that 
antibiotic resistance spreads across borders through 
many vectors. Tamar Barlam and Kalpana Gupta 
highlight the medical evidence that underpins the 
conclusion that resistance is a transnational health 
risk and thus a truly global problem.6 Even countries 
with extraordinary programs in antibiotic steward-
ship can face multi-drug resistant diseases when a 
traveler returns home from abroad.
While medical evidence is central to this effort, nar-
row disciplinary perspectives can hinder a full view of 
the field. To a physician, ABR is salient when a patient 
in the intensive care ward develops an untreatable 
and deadly bacterial infection. The problem is a lack 
of new drugs and the solution is to develop new treat-
ments. To an infection control specialist, the problem 
is the nosocomial transmission of multi-drug resistant 
pathogens in hospitals. Solutions include better hos-
pital infection control, including active surveillance. 
Public health officials might look even further back, at 
the chain of events that allowed multi-drug resistant 
bacteria to evolve due to improper antibiotic steward-
ship, including perhaps indiscriminate use of antibiot-
ics among both humans and animals. 
None of these disciplinary perspectives are wrong, 
but they give a limited view of a complex systems 
problem. For this reason, we sought from the begin-
ning to include people from diverse academic and 
professional disciplines in this project, including phy-
sicians, public health practitioners, epidemiologists, 
economists, historians, lawyers, political scientists, 
and social activists — all of whom were committed to 
advancing global health, especially among the poorest 
populations on the planet. ABR is a complex problem, 
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one best addressed through interdisciplinary work 
including academics, clinicians and policymakers 
across varied contexts.
Our interdisciplinary approach yielded a three-
pronged approach to tackling ABR: (1) Access, (2) 
Conservation, and (3) Innovation (see Figure 1).7
Access, or lack thereof, is the cause of more peo-
ple dying today from susceptible bacteria than from 
resistant bacterial pathogens,8 despite warnings of 
a looming antibiotic apocalypse.9 Inadequate access 
to existing antibiotics is a global health crisis of the 
first order that currently receives insufficient atten-
tion. But antibiotic access cannot stand alone as a 
solution. Promoting global access to antibiotics will 
speed resistance unless it is coupled with strong con-
servation programs to ensure appropriate use. Access 
and conservation themselves may actually work at 
cross-purposes unless integrated into a single pro-
gram. In addition, achieving universal access for 
low- and middle-income populations could under-
mine commercial incentives to invest in the research 
and development (R&D) necessary to bring innova-
tive new antibiotics to market. The article by Nils 
Daulaire and colleagues takes a bold stance on the 
crisis of antibiotic access, but they also recognize the 
imperative to integrate the solution with both con-
servation and innovation. While access could pos-
sibly be addressed on a country-by-country basis, 
an integrated solution requires coordinated action 
across borders.
Conservation cannot stop resistance, but it can cer-
tainly slow the rate of the emergence and spread of 
multi-drug resistant organisms. Conservation slows 
the rate of bacterial evolution, buying us time to 
develop alternatives. Conservation also includes activ-
ities that are welcome even in the absence of resistance 
because preventing an infection is always better than 
treating one. Public health measures like vaccines, 
clean food, safe drinking water, and infection control 
all support conservation by reducing the demand for 
antibiotics in the first instance.10 But conservation, 
despite many positive attributes, also faces obstacles. 
Conservation attempts to limit the inappropriate use 
of antibiotics, but the difficulty lies in defining “inap-
propriate,” including use in resource-poor settings 
where access is the most pressing problem. Further-
more, conservation programs reduce the demand for 
antibiotics, which may encourage pharmaceutical and 
biotechnology companies to flee the field. Few com-
panies want to step up R&D investments in a declin-
ing market. Most importantly, conservation is a global 
collective action problem: while most conservation 
efforts will be implemented nationally, they work 
best when every country participates. For some coun-
tries, financial support will be necessary, as recently 
articulated in the World Health Organization’s Global 
Action Plan on Antimicrobial Resistance.11
Innovation is the third leg of the tripod. We clearly 
need new antibiotic drugs to tackle emerging multi-
drug resistant diseases and the market is not respond-
ing adequately to the challenge.12 Traditional drug 
Figure 1
Policy Tripod for Addressing Antibiotic Resistance
Our interdisciplinary 
approach yielded a three-
pronged approach to 
tackling ABR: (1) Access, 
(2) Conservation, and (3) 
Innovation.
Access without 
conservation and 
innovation will speed 
resistance
Conservation 
constrains access 
and undermines 
Innovation
Innovation 
without access 
is unjust, and 
without 
conservation 
it’s wasteful.
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innovation models would promote either higher prices 
or larger volumes in order to drive innovation, but for 
antibiotics, the first would constrain access and the 
latter might undermine conservation. Crafting an 
effective new innovation model for antibiotics is nec-
essarily a global endeavor, as described in this series 
by Manica Balasegaram, Charles Clift, and John-Arne 
Røttingen.13 They propose new global institutional 
arrangements to fund R&D and reward innovation for 
antibiotics, harmonized with the goals of access and 
conservation.
Learning from Different Perspectives
To broaden our understanding of the problem, this 
series also explores four additional disciplinary per-
spectives on ABR, rooted in history, economics, “One 
Health,” and the environment. The recent work on the 
history of antibiotics is vibrant, woven together in the 
article by Scott Podolsky and colleagues.14 The antibi-
otic era is only seven decades old, but our collective 
memories need refreshing. Most salient to the present 
efforts are issues of who controls the use of antibiot-
ics. Conservation and stewardship programs today are 
marching into prescriber autonomy battles that have 
been underway for decades in many settings. They 
also remind us that the current regulatory regime for 
prescription drugs was largely a response to problems 
with safety and efficacy of antibiotics. This is a timely 
reminder since the U.S. Food & Drug Administration 
and European Medicines Agency have greatly relaxed 
those standards in recent years, specifically to boost 
antibiotic innovation.
Three key points arise from the economic analysis 
by Aidan Hollis and Peter Maybarduk.15 First, antibi-
otics are a global public good and the solution must 
address the “commons” problem. If we treated antibi-
otics as uniquely valuable and exhaustible, we would 
stop using them in low-value ways like animal growth 
promotion and human viral infections. Second, from 
an economics perspective, addressing the triad of 
access, conservation and innovation requires global 
coordination, as national-level solutions would be vul-
nerable to free riding, perverse financial incentives, 
and inadequate commitment mechanisms. Finally, 
they apply the work of Elinor Ostrom on the design 
and governance of coalitions to manage commons to 
emerging global governance options for antibiotics.
The One Health movement seeks to understand the 
many linkages between human and animal health, 
integrating approaches to improve planetary health. 
The task given to Anthony So and colleagues was 
expansive, and could easily have been the subject of 
its own series. But the primary message shines clearly 
through the mounds of data: human health and ani-
mal health are deeply intertwined and therefore any 
solution to ABR must include, as a core component, 
animal health.16 It might be tempting to “simplify” 
the solution by cabining animal issues in a separate 
response, but that would be a profound mistake. 
The final perspective article by Steinar Andresen 
and Steven J. Hoffman reminds us that ABR is not 
the only global collective action problem and that we 
have much to learn from how other sectors address 
“commons” problems like it.17 Their article benefits 
from the decades that Andresen has spent studying 
multilateral environmental agreements, first relating 
to oceans and more recently to climate change. They 
argue that while the international system is inherently 
weak, states can craft agreements to achieve global 
collective action if they are designed appropriately. In 
other words, institutional design matters. Learning 
from the environment, effective agreements include 
good procedures for reporting, enhancing compliance, 
and supporting implementation. Non-state actors 
must be engaged and mixed legal/political approaches 
should be considered.
Moving Towards Global Collective Action
The series ends with four articles that explore the 
mechanisms, instruments and forums available to 
states for achieving global collective action on ABR. 
Steven J. Hoffman and Trygve Ottersen highlight the 
need to put accountability at the core of any interna-
tional agreement for it to achieve real-world impact.18 
They start by defining “accountability” — a term used 
too often in so many different ways — as a relation-
ship involving answerability and enforceability. Build-
ing on this definition, they sketch out a taxonomy of 
accountability mechanisms covering transparency, 
oversight, complaint and enforcement. This taxonomy 
then serves as a menu of options for global decision-
makers to embed accountability into the core of any 
kind of international agreement, either for ABR or 
other issues. Like guests at a restaurant, they do not 
recommend ordering every item from the menu. That 
might be unhealthy. But in the absence of empirical 
studies evaluating each mechanism’s effectiveness, 
they advise global decision-makers to incorporate at 
least one mechanism from each category and rigor-
ously evaluate their impact.
Questions around the exact kind of international 
instrument needed to address ABR are taken up in 
the next article by Steven J. Hoffman, John-Arne Røt-
tingen and Julio Frenk, who make a strong argument 
in favor of pursuing an international legal approach.19 
Whereas all three co-authors have previously taken 
stands against the adoption of new global health 
laws,20 they see something different in ABR. Specifi-
Hoffman and Outterson
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cally, they think it is the only health challenge for which 
an international legal approach has thus far been pro-
posed whereby (1) the problem has a significant trans-
national dimension, (2) the solution justifies the use of 
an instrument with coercive features, (3) the outcome 
of utilizing international law is likely beneficial, and 
(4) the implementation of needed actions have not 
been achieved through other instruments. These four 
features, which the trio put forward elsewhere as a cri-
teria for considering new global health laws,21 make 
ABR uniquely well-suited for international legal inter-
vention among the range of issues that vie for global 
decision-makers’ attention. 
Should the decision be made to pursue negotia-
tion of an ABR international legal agreement, then 
the exact content of such an agreement will need to 
be crafted. Asha Behdinan and colleagues take up 
this challenge by assessing ten possible global ABR 
policies covering access, conservation and innova-
tion and dividing them into three categories: those 
policies that depend on legalization to be effective 
(mostly conservation); those policies that would be 
strengthened if legalized (mostly access); and those 
that could be pursued separately but which might 
help mobilize support for implementation of the 
other ABR policies if included as part of a grand 
bargain (mostly innovation).22 The vitally important 
argument is that some conservation policies that are 
desperately needed to address ABR might be impos-
sible to implement without the strength of an inter-
national legal agreement behind them. The collective 
action problems undermining action in some areas 
are just too great.
Following selection of the most appropriate inter-
national instrument, a decision about the most appro-
priate convening forum for pursing it will need to be 
made. Zain Rizvi and Steven J. Hoffman argue that 
just as much attention should be given to how and 
where global collective action on ABR is facilitated as 
the specific actions that are needed.23 This is because 
the success of any international agreement depends 
greatly on where it is negotiated and implemented. In 
their article, the two co-authors evaluate four different 
forums though which states could develop an interna-
tional legal agreement: self-organized venue; World 
Health Organization (WHO); World Trade Organiza-
tion; and United Nations General Assembly (UNGA). 
While WHO and UNGA seem particularly promising, 
ultimately it is clear that an effective response is prob-
ably best coordinated through linked action pursued 
through several forums.
Concluding Thoughts
So, what kind of actions must be taken to address the 
global threat of ABR? Every article in this series points 
towards a common goal: the highest level of global 
collective action possible across countries, spanning 
sectors, and among all relevant stakeholders. What 
legal, political and economic tools might be needed to 
achieve this level of action? Each article reveals differ-
ent lessons to be learned. While an international legal 
framework addressing ABR is recommended, such 
a framework is still only an implementation vehicle 
for other tools — whether those are global standards, 
funding agreements, industry engagement, monitored 
benchmarks, market incentives, or accountability 
mechanisms.
Our goal for this series was to start providing evi-
dence-informed guidance for how states and non-
state actors could muster a comprehensive response 
Our goal for this series was to start providing evidence-informed guidance  
for how states and non-state actors could muster a comprehensive 
response to the global threat of ABR — addressing the access, conservation 
and innovation imperatives — while inspiring new lines of inquiry. We 
acknowledge this work is only a start because we know that much additional 
research and analysis is needed. Our real innovation here is having taken 
a scientific approach to global strategy whereby we drew upon a range 
of disciplines to systematically assess how instruments, institutions and 
initiatives could be designed to foster collective action on ABR and maximize 
impact. Our hope is that many more researchers, policymakers, activists, and 
social commentators will join the fray and continue this important work. 
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to the global threat of ABR — addressing the access, 
conservation and innovation imperatives — while 
inspiring new lines of inquiry. We acknowledge this 
work is only a start because we know that much 
additional research and analysis is needed. Our real 
innovation here is having taken a scientific approach 
to global strategy whereby we drew upon a range of 
disciplines to systematically assess how instruments, 
institutions and initiatives could be designed to fos-
ter collective action on ABR and maximize impact.24 
Our hope is that many more researchers, policymak-
ers, activists, and social commentators will join the 
fray and continue this important work. If we wait 
too long, we might end up missing today’s policy 
window that has been created by the Global Health 
Security Agenda launch in February 2014, the adop-
tion of WHO’s Global Action Plan on Antimicrobial 
Resistance in May 2015, the White House Forum on 
Antibiotic Stewardship and the G7’s communiqué in 
June 2015, and the ongoing O’Neill Review on Anti-
microbial Resistance in the United Kingdom, among 
many other contributing efforts and events. 
We have many reasons to be hopeful. In the same 
month as this series is published, Professor Otto Cars, 
a grandfather of the ABR research field (and co-author 
of the second article in this series), was awarded Swe-
den’s H.M. The King’s Medal for his contributions to 
medical science. It demonstrates, in Professor Cars’s 
own words, that ABR research “in the twilight zone in-
between science and politics is officially being recog-
nized.”25 We have also started to hear from the world’s 
wealthiest countries that they are prepared to use pub-
lic money to support antibiotics innovation. A major 
injection of sustainable financing for R&D of antibi-
otics could transform the ABR challenge and provide 
the necessary political leverage to achieve progress on 
the access and conservation imperatives as well.
We conclude by thanking everyone who made this 
series possible, including all of our authors, peer-
reviewers, coordinators, and publishers. We are espe-
cially pleased with the timely process at JLME and our 
partners’ commitment to open-access publication. 
We hope you enjoy reading the series as much as we 
enjoyed editing it.
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